Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)

Authors not listed

Eli Lilly and Company · 2014

Abstract

The purpose of this study is to test whether an investigational drug called solanezumab can slow the progression of memory problems associated with brain amyloid (protein that forms plaques in the brains of people with Alzheimer Disease \[AD\]).

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-10-26 MST

Cite this

APA
Anonymous. (2014). Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study). <em>Eli Lilly and Company</em>. https://clinicaltrials.gov/study/NCT02008357
Vancouver
Anonymous. Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study). Eli Lilly and Company. 2014.
BibTeX
@misc{anon2014AntiAm, title = {Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)}, author = {Anonymous}, journal = {Eli Lilly and Company}, year = {2014}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings